Nephron Pharmaceuticals

Nephron Pharmaceuticals is a major private manufacturer of generic respiratory medications and a 503B outsourcing provider, headquartered in West Columbia, South Carolina. Founded in 2004 but leveraging over 27 years of industry legacy, it operates an 840,000+ square foot automated facility capable of producing over one billion doses daily. The company focuses on contract manufacturing, generic drug production, and mitigating national drug shortages, positioning itself as a critical domestic supplier in the sterile injectable and inhalation markets.

Large-scale, fully automated sterile manufacturing platform utilizing blow-fill-seal (BFS) and other advanced aseptic processing technologies for the production of generic inhalation solutions, suspensions, injectables, and ophthalmic medications.

Nephron competes with large publicly-traded CDMOs (e.g., Catalent, Lonza) and other generic sterile injectable manufacturers (e.g., Hikma, Pfizer's Hospira). In the 503B space, it competes with other outsourcing facilities like Fagron Sterile Services and QuVa Pharma. Its differentiation lies in its massive scale of automated production, specific focus on respiratory generics, woman-owned status, and strong messaging around domestic production and shortage mitigation.